Literature DB >> 20832403

A synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in rats.

Marylou V Solbrig1, Yijun Fan, Neal Hermanowicz, Maria Grazia Morgese, Andrea Giuffrida.   

Abstract

Chronic CNS infection by several families of viruses can produce deficits in prefrontal cortex (PFC) and striatal function. Cannabinoid drugs have been long known for their anti-inflammatory properties and their ability to modulate adult neuro and gliogenesis. Therefore, we explored the effects of systemic administration of the cannabinoid agonist WIN55,212-2(WIN) on prefrontal cortex (PFC) and striatal cytogenesis in a viral model of CNS injury and inflammation based on Borna Disease (BD) virus encephalitis. Active BrdU(+) progenitor populations were significantly decreased 1 week after BrdU labeling in BD rats [p<0.001 compared to uninfected (NL) controls] while less than 5% of BrdU(+) cells colabeled for BDV protein. Systemic WIN (1mg/kg i.p. twice daily×7 days) increased the survival of BrdU(+) cells in striatum (p<0.001) and PFC of BD rats, with differential regulation of labeled oligodendroglia precursors vs microglia/macrophages. WIN increased the percentage of BrdU(+) oligodendrocyte precursor cells and decreased BrdU(+) ED-1-labeled phagocytic cells, without producing pro- or antiviral effects. BDV infection decreased the levels of the endocannabinoid anandamide (AEA) in striatum (p<0.05 compared to NL rats), whereas 2-AG levels were unchanged. Our findings indicate that: 1) viral infection is accompanied by alterations of AEA transmission in the striatum, but new cell protection by WIN appears independent of its effect on endocannabinoid levels; and 2) chronic WIN treatment alters the gliogenic cascades associated with CNS injury, promoting oligodendrocyte survival. Limiting reactive gliogenesis and macrophage activity in favor of oliogodendroglia development has significance for demyelinating diseases. Moreover, the ability of cannabinoids to promote the development of biologically supportive or symbiotic oligodendroglia may generalize to other microglia-driven neurodegenerative syndromes including NeuroAIDS and diseases of aging.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832403      PMCID: PMC2981070          DOI: 10.1016/j.expneurol.2010.09.003

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  87 in total

1.  Tardive dyskinetic syndrome in rats infected with Borna disease virus.

Authors:  M V Solbrig; G F Koob; J H Fallon; W I Lipkin
Journal:  Neurobiol Dis       Date:  1994-12       Impact factor: 5.996

2.  Prefrontal cortex dysfunction in Borna disease virus (BDV)--infected rats.

Authors:  M V Solbrig; G F Koob; J H Fallon; S Reid; W I Lipkin
Journal:  Biol Psychiatry       Date:  1996-10-01       Impact factor: 13.382

3.  Determination of immune cells and expression of major histocompatibility complex class II antigen in encephalitic lesions of experimental Borna disease.

Authors:  U Deschl; L Stitz; S Herzog; K Frese; R Rott
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

4.  Borna disease virus replicates in astrocytes, Schwann cells and ependymal cells in persistently infected rats: location of viral genomic and messenger RNAs by in situ hybridization.

Authors:  K M Carbone; T R Moench; W I Lipkin
Journal:  J Neuropathol Exp Neurol       Date:  1991-05       Impact factor: 3.685

5.  Reduced basal ganglia volume in HIV-1-associated dementia: results from quantitative neuroimaging.

Authors:  E H Aylward; J D Henderer; J C McArthur; P D Brettschneider; G J Harris; P E Barta; G D Pearlson
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

6.  Evidence of human immunodeficiency virus type 1 infection of nestin-positive neural progenitors in archival pediatric brain tissue.

Authors:  Lynnae Schwartz; Lucy Civitello; Anastasie Dunn-Pirio; Samantha Ryschkewitsch; Elizabeth Berry; Winston Cavert; Nikilyn Kinzel; Diane M P Lawrence; Rohan Hazra; Eugene O Major
Journal:  J Neurovirol       Date:  2007-06       Impact factor: 2.643

7.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

8.  Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation.

Authors:  H G Kuhn; H Dickinson-Anson; F H Gage
Journal:  J Neurosci       Date:  1996-03-15       Impact factor: 6.167

Review 9.  Borna disease--neuropathology and pathogenesis.

Authors:  G Gosztonyi; H Ludwig
Journal:  Curr Top Microbiol Immunol       Date:  1995       Impact factor: 4.291

10.  Monoclonal antibody to Theiler's murine encephalomyelitis virus defines a determinant on myelin and oligodendrocytes, and augments demyelination in experimental allergic encephalomyelitis.

Authors:  M Yamada; A Zurbriggen; R S Fujinami
Journal:  J Exp Med       Date:  1990-06-01       Impact factor: 14.307

View more
  15 in total

Review 1.  PET imaging in multiple sclerosis.

Authors:  Daniele de Paula Faria; Sjef Copray; Carlos Buchpiguel; Rudi Dierckx; Erik de Vries
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-09       Impact factor: 4.147

Review 2.  Cannabinoids and glial cells: possible mechanism to understand schizophrenia.

Authors:  Valéria de Almeida; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-02-01       Impact factor: 5.270

3.  Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain.

Authors:  Chia-Shan Wu; Christopher P Jew; Hui-Chen Lu
Journal:  Future Neurol       Date:  2011-07-01

Review 4.  New insights on endocannabinoid transmission in psychomotor disorders.

Authors:  Andrea Giuffrida; Alexandre Seillier
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-04-10       Impact factor: 5.067

5.  Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes.

Authors:  Valéria de Almeida; Gabriela Seabra; Guilherme Reis-de-Oliveira; Giuliana S Zuccoli; Priscila Rumin; Mariana Fioramonte; Bradley J Smith; Antonio W Zuardi; Jaime E C Hallak; Alline C Campos; José A Crippa; Daniel Martins-de-Souza
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-27       Impact factor: 5.760

6.  WIN55,212-2 protects oligodendrocyte precursor cells in stroke penumbra following permanent focal cerebral ischemia in rats.

Authors:  Jing Sun; Yin-quan Fang; Hong Ren; Tao Chen; Jing-jing Guo; Jun Yan; Shu Song; Lu-yong Zhang; Hong Liao
Journal:  Acta Pharmacol Sin       Date:  2012-12-03       Impact factor: 6.150

Review 7.  Strategies for protecting oligodendrocytes and enhancing remyelination in multiple sclerosis.

Authors:  Jane M Rodgers; Andrew P Robinson; Stephen D Miller
Journal:  Discov Med       Date:  2013-08       Impact factor: 2.970

Review 8.  Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications.

Authors:  Marisol S Castaneto; David A Gorelick; Nathalie A Desrosiers; Rebecca L Hartman; Sandrine Pirard; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2014-08-18       Impact factor: 4.492

Review 9.  Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies.

Authors:  Mauro Maccarrone; Manuel Guzmán; Ken Mackie; Patrick Doherty; Tibor Harkany
Journal:  Nat Rev Neurosci       Date:  2014-12       Impact factor: 38.755

10.  Targeted multiplexed selected reaction monitoring analysis evaluates protein expression changes of molecular risk factors for major psychiatric disorders.

Authors:  Hendrik Wesseling; Michael G Gottschalk; Sabine Bahn
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.